MCID: BRL010
MIFTS: 54

Buruli Ulcer

Categories: Genetic diseases, Infectious diseases, Rare diseases, Skin diseases

Aliases & Classifications for Buruli Ulcer

MalaCards integrated aliases for Buruli Ulcer:

Name: Buruli Ulcer 58 77 54 56 45 17 74
Buruli Ulcer, Susceptibility to 58 30 13 6 41
Buruli Ulcer Disease 12 54 15
Mycobacterium Ulcerans, Susceptibility to 58
Mycobacterium Ulcerans 58
Bairnsdale Ulcer 12
Daintree Ulcer 12
Searle's Ulcer 12
Mossman Ulcer 12
Searl Ulcer 12
Bud 54

Classifications:



External Ids:

Disease Ontology 12 DOID:0050456
OMIM 58 610446
MeSH 45 D054312
NCIt 51 C84604
SNOMED-CT 69 15845006
ICD10 34 A31.1
UMLS 74 C0085568

Summaries for Buruli Ulcer

OMIM : 58 Buruli ulcer is an infectious disease prevalent in many tropical and subtropical regions caused by infection with Mycobacterium ulcerans. It is the third most frequent mycobacterial disease in humans worldwide, after tuberculosis (607948) and leprosy (246300). Lesions are most common on exposed parts of the body, especially the limbs. Buruli ulcer derives its name from a county in Uganda, East Africa, north of Kampala, where the disease was found in the late 1950s in hundreds of people living near marshes and riverine areas near the Nile River (Clancey et al., 1961; Barker, 1971). The disease was first described in the medical literature in 1948 in a report on patients in Australia (MacCallum et al., 1948). Patients have also been reported from tropical areas in Latin America and Asia (Stienstra et al., 2006; van der Werf et al., 2005). (610446)

MalaCards based summary : Buruli Ulcer, also known as buruli ulcer, susceptibility to, is related to leprosy 3 and bacterial infectious disease, and has symptoms including nodule An important gene associated with Buruli Ulcer is SLC11A1 (Solute Carrier Family 11 Member 1), and among its related pathways/superpathways are Innate Immune System and Immune response NFAT in immune response. The drugs Streptomycin and Rifampicin have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and lung, and related phenotypes are digestive/alimentary and endocrine/exocrine gland

Disease Ontology : 12 A primary bacterial infectious disease that results in infection located in skin or located in subcutaneous tissue, has material basis in Mycobacterium ulcerans, which could be transmitted by insects. The bacterium produces a toxin, named mycolactone, which causes subcutaneous fat necrosis and inhibits an immune response. The infection has symptom nodule, which is a painless, mobile swelling in the skin.

Wikipedia : 77 Buruli ulcer is an infectious disease caused by Mycobacterium ulcerans. The early stage of the infection... more...

Related Diseases for Buruli Ulcer

Diseases related to Buruli Ulcer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 314)
# Related Disease Score Top Affiliating Genes
1 leprosy 3 30.7 IFNG IL10 SLC11A1
2 bacterial infectious disease 30.5 IFNG IL10 SLC11A1
3 schistosomiasis 29.7 CD40LG IFNG IL10 IL4
4 allergic contact dermatitis 29.6 IFNG IL10 IL4
5 contact dermatitis 29.6 IFNG IL10 IL4
6 mycoplasma pneumoniae pneumonia 29.6 IFNG IL10 IL4
7 aspergillosis 29.6 IFNG IL10 IL4
8 pulmonary tuberculosis 29.4 IFNG IL10 IL4 SLC11A1
9 rheumatoid arthritis 29.2 CD40LG IFNG IL10 IL4 SLC11A1
10 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 28.8 CD40LG IFNG IL10 IL4 WAS
11 renal hypodysplasia/aplasia 1 11.4
12 bronchogenic cyst 11.3
13 cephalic disorders 11.2
14 solitary median maxillary central incisor 11.0
15 incisors, fused mandibular 11.0
16 thiourea tasting 11.0
17 liebenberg syndrome 11.0
18 hyperinsulinemic hypoglycemia, familial, 2 11.0
19 optic papillitis 11.0
20 tongue disease 11.0
21 colorectal cancer 10.6
22 mycobacterium marinum 10.5
23 adenocarcinoma 10.4
24 cephalosporin allergy 10.4 IFNG IL10
25 campylobacteriosis 10.4 IFNG SLC11A1
26 idiopathic achalasia 10.4 IL10 LOC111365141
27 chronic graft versus host disease 10.4 IFNG IL10
28 clonorchiasis 10.3 IFNG IL10
29 tuberculoid leprosy 10.3 IFNG IL10
30 fungal meningitis 10.3 IFNG IL10
31 osteomyelitis 10.3
32 stomatitis 10.3
33 multicentric castleman disease 10.3 IFNG IL10
34 extrapulmonary tuberculosis 10.3 IFNG IL10 SLC11A1
35 testicular disease 10.3 IFNG IL10 SLC11A1
36 human immunodeficiency virus type 1 10.3
37 oral squamous cell carcinoma 10.3
38 chronic active epstein-barr virus infection 10.3 IFNG IL10
39 lymphadenitis 10.3 IFNG IL10 SLC11A1
40 african tick-bite fever 10.3 CD40LG IFNG
41 plasmodium falciparum malaria 10.3 HBB IFNG IL10
42 ascaridiasis 10.3 IL10 NELFCD
43 squamous cell carcinoma 10.2
44 peanut allergy 10.2 IFNG IL10
45 fascioliasis 10.2 IFNG IL10
46 iron overload in africa 10.2 HBB SLC11A1
47 influenza 10.2
48 tropical endomyocardial fibrosis 10.2 IL10 IL4
49 endomyocardial fibrosis 10.2 IL10 IL4
50 pulmonary alveolar microlithiasis 10.2

Graphical network of the top 20 diseases related to Buruli Ulcer:



Diseases related to Buruli Ulcer

Symptoms & Phenotypes for Buruli Ulcer

Clinical features from OMIM:

610446

Symptoms:

12
  • nodule

MGI Mouse Phenotypes related to Buruli Ulcer:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.43 ATF4 IFNG IL10 IL4 SLC11A1 WAS
2 endocrine/exocrine gland MP:0005379 9.17 ATF4 CD40LG IFNG IL10 IL4 SEC61A1

Drugs & Therapeutics for Buruli Ulcer

Drugs for Buruli Ulcer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 15)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Streptomycin Approved, Vet_approved Phase 2, Phase 3,Phase 3,Not Applicable 57-92-1 19649
2
Rifampicin Approved Phase 2, Phase 3,Phase 3,Not Applicable 13292-46-1 5381226 5458213
3
Clarithromycin Approved Phase 2, Phase 3,Phase 3 81103-11-9 84029
4 Anti-Infective Agents Phase 2, Phase 3,Phase 3,Not Applicable
5 Anti-Bacterial Agents Phase 2, Phase 3,Phase 3,Not Applicable
6 Antibiotics, Antitubercular Phase 2, Phase 3,Phase 3,Not Applicable
7 Antitubercular Agents Phase 2, Phase 3,Phase 3,Not Applicable
8 Cytochrome P-450 CYP3A Inducers Phase 2, Phase 3,Phase 3,Not Applicable
9 Nucleic Acid Synthesis Inhibitors Phase 2, Phase 3,Phase 3,Not Applicable
10 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3,Phase 3
11 Cytochrome P-450 CYP3A Inhibitors Phase 2, Phase 3,Phase 3
12
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
13 Antiparasitic Agents Phase 2
14 Antiprotozoal Agents Phase 2
15 Antimalarials Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 BURULICO Drug Trial Study Protocol: RCT SR8/SR4+CR4, GHANA Completed NCT00321178 Phase 2, Phase 3 SR4 - switch to CR4
2 WHO Drug Study for Buruli Ulcer - Comparison of SR8 and CR8 Active, not recruiting NCT01659437 Phase 2, Phase 3 Clarithromycin Extended Release;Streptomycin intramuscular injection
3 Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana Completed NCT02281643 Phase 2 Doxycycline
4 Pathogenesis and Management of M. Ulcerans Disease, Buruli Ulcer Unknown status NCT02153034
5 Timing of Surgical Intervention in Buruli Ulcer Patients Treated With Antibiotics Unknown status NCT01432925 Not Applicable
6 Treat Early and Broad: Thermotherapy of Buruli Ulcer Integrated Into WHOrecommended Wound Management in West Africa Recruiting NCT03957447
7 Integrated Mapping of Skin-presenting Neglected Tropical Diseases in Liberia Recruiting NCT03683745

Search NIH Clinical Center for Buruli Ulcer

Cochrane evidence based reviews: buruli ulcer

Genetic Tests for Buruli Ulcer

Genetic tests related to Buruli Ulcer:

# Genetic test Affiliating Genes
1 Buruli Ulcer, Susceptibility to 30 SLC11A1

Anatomical Context for Buruli Ulcer

MalaCards organs/tissues related to Buruli Ulcer:

42
Skin, Bone, Lung, T Cells, Tongue, Breast, Heart

The Foundational Model of Anatomy Ontology organs/tissues related to Buruli Ulcer:

20
Skin Or

Publications for Buruli Ulcer

Articles related to Buruli Ulcer:

(show top 50) (show all 466)
# Title Authors Year
1
Comparison of Mycobacterium ulcerans (Buruli ulcer) and Leptospira sp. (Leptospirosis) dynamics in urban and rural settings. ( 30615683 )
2019
2
Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening. ( 30689630 )
2019
3
The compound TB47 is highly bactericidal against Mycobacterium ulcerans in a Buruli ulcer mouse model. ( 30705268 )
2019
4
Mycobacterium ulcerans Population Genomics To Inform on the Spread of Buruli Ulcer across Central Africa. ( 30728280 )
2019
5
Confirmed Case of Buruli Ulcer, Senegal, 2018. ( 30789331 )
2019
6
The paediatric participation scale measuring participation restrictions among former Buruli Ulcer patients under the age of 15 in Ghana and Benin: Development and first validation results. ( 30870426 )
2019
7
Decrease in Mycobacterium ulcerans disease (Buruli ulcer) in the Lalo District of Bénin (West Africa). ( 30871489 )
2019
8
Molecular Docking and Dynamics Simulation Studies Predict Munc18b as a Target of Mycolactone: A Plausible Mechanism for Granule Exocytosis Impairment in Buruli Ulcer Pathogenesis. ( 30934618 )
2019
9
The gendered impact of Buruli ulcer on the household production of health and social support networks: Why decentralization favors women. ( 30986205 )
2019
10
WHO takes a new approach to Buruli ulcer. ( 31034395 )
2019
11
Shortening Buruli ulcer treatment with combination therapy targeting the respiratory chain and exploiting M. ulcerans gene decay. ( 31036687 )
2019
12
Challenges associated with the treatment of Buruli ulcer. ( 30168876 )
2019
13
Subcutaneous Granulomatous Inflammation due to Basidiobolomycosis: Case Reports of 3 Patients in Buruli Ulcer Endemic Areas in Benin. ( 29545962 )
2018
14
Delayed versus standard assessment for excision surgery in patients with Buruli ulcer in Benin: a randomised controlled trial. ( 29605498 )
2018
15
Tackling the worsening epidemic of Buruli ulcer in Australia in an information void: time for an urgent scientific response. ( 29642808 )
2018
16
A severe case of <em>Mycobacterium ulcerans</em> (Buruli ulcer) osteomyelitis requiring a below-knee amputation. ( 29642809 )
2018
17
Microdeletion on chromosome 8p23.1 in a familial form of severe Buruli ulcer. ( 29708969 )
2018
18
A protocol for culturing environmental strains of the Buruli ulcer agent, Mycobacterium ulcerans. ( 29712992 )
2018
19
Molecular detection of Mycobacterium ulcerans in the environment and its relationship with Buruli ulcer occurrence in Zio and Yoto districts of maritime region in Togo. ( 29782522 )
2018
20
Targeting the Mycobacterium ulcerans cytochrome bc1:aa3 for the treatment of Buruli ulcer. ( 30560872 )
2018
21
Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer. ( 30559131 )
2018
22
Treatment for Buruli ulcer: the long and winding road to antimicrobials-first. ( 30556580 )
2018
23
Buruli Ulcer: a Review of the Current Knowledge. ( 30460172 )
2018
24
Buruli ulcer in southern Côte D'ivoire: dynamic schemes of perception and interpretation of modes of transmission. ( 30376901 )
2018
25
Epidemiology of Buruli Ulcer Infections, Victoria, Australia, 2011-2016. ( 30334704 )
2018
26
The association of rainfall and Buruli ulcer in southeastern Australia. ( 30222751 )
2018
27
Implementing active community-based surveillance-response system for Buruli ulcer early case detection and management in Ghana. ( 30208037 )
2018
28
Surgery for Buruli ulcer in the antibiotic era. ( 30152360 )
2018
29
Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease). ( 30136733 )
2018
30
Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer. ( 30102705 )
2018
31
Improving clinical and epidemiological predictors of Buruli ulcer. ( 30080870 )
2018
32
Tackling the worsening epidemic of Buruli ulcer in Australia in an information void: time for an urgent scientific response. ( 30071818 )
2018
33
Sec61 blockade by mycolactone: A central mechanism in Buruli ulcer disease. ( 30055020 )
2018
34
Perception and incidence of Buruli ulcer in Ogun State, South West Nigeria: intensive epidemiological survey and public health intervention recommended. ( 30050630 )
2018
35
In Silico Screening of Isocitrate Lyase for Novel Anti-Buruli Ulcer Natural Products Originating from Africa. ( 29954088 )
2018
36
Laboratory confirmation of Buruli ulcer cases in Ghana, 2008-2016. ( 29870529 )
2018
37
Surgery for Buruli ulcer in the antibiotic era. ( 29605497 )
2018
38
Developing a Buruli ulcer community of practice in Bankim, Cameroon: A model for Buruli ulcer outreach in Africa. ( 29584724 )
2018
39
The incubation period of Buruli ulcer (Mycobacterium ulcerans infection) in Victoria, Australia - Remains similar despite changing geographic distribution of disease. ( 29554096 )
2018
40
Diagnostic Tests for Buruli Ulcer: Clinical Judgment Revisited. ( 29538643 )
2018
41
Diagnostic Accuracy of Clinical and Microbiological Signs in Patients With Skin Lesions Resembling Buruli Ulcer in an Endemic Region. ( 29538642 )
2018
42
Implementation of a decentralized community-based treatment program to improve the management of Buruli ulcer in the Ouinhi district of Benin, West Africa. ( 29529087 )
2018
43
Report of a series of 82 cases of Buruli ulcer from Nigeria treated in Benin, from 2006 to 2016. ( 29522516 )
2018
44
Comparative Genomics Shows That Mycobacterium ulcerans Migration and Expansion Preceded the Rise of Buruli Ulcer in Southeastern Australia. ( 29439984 )
2018
45
Perceived causes and risk factors of Buruli ulcer among patients at Agogo Presbyterian hospital in Ashanti Region of Ghana. ( 29361986 )
2018
46
Risk factors for Mycobacterium ulcerans infection (Buruli Ulcer) in Togo ─ a case-control study in Zio and Yoto districts of the maritime region. ( 29351741 )
2018
47
Buruli Ulcer: Review of a Neglected Skin Mycobacterial Disease. ( 29343539 )
2018
48
Buruli Ulcer, a Prototype for Ecosystem-Related Infection, Caused by Mycobacterium ulcerans. ( 29237707 )
2018
49
Mapping biopsy for Buruli ulcer self-medicated with occlusive dressing. ( 28891259 )
2018
50
Mycobacterium ulcerans infection (Buruli ulcer) in French Guiana, South America, 1969-2013: an epidemiological study. ( 29851583 )
2017

Variations for Buruli Ulcer

ClinVar genetic disease variations for Buruli Ulcer:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 SLC11A1 NM_000578.3(SLC11A1): c.1627G> A (p.Asp543Asn) single nucleotide variant risk factor rs17235409 GRCh37 Chromosome 2, 219259732: 219259732
2 SLC11A1 NM_000578.3(SLC11A1): c.1627G> A (p.Asp543Asn) single nucleotide variant risk factor rs17235409 GRCh38 Chromosome 2, 218395009: 218395009

Expression for Buruli Ulcer

Search GEO for disease gene expression data for Buruli Ulcer.

Pathways for Buruli Ulcer

Pathways related to Buruli Ulcer according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.8 CD40LG HBB IFNG IL10 IL4 SEC61A1
2
Show member pathways
12.43 CD40LG IFNG IL10 IL4
3 12.35 CD40LG IFNG IL10 IL4
4
Show member pathways
12.01 CD40LG IFNG IL10 IL4
5
Show member pathways
11.89 CD40LG IFNG IL10 IL4 WAS
6 11.79 IFNG IL10 IL4
7 11.63 IFNG WAS WASL
8 11.59 IFNG IL10 IL4
9
Show member pathways
11.55 CD40LG IFNG IL4
10 11.5 IFNG IL10 IL4
11 11.43 CD40LG IL10 IL4
12 11.24 IFNG IL10 IL4
13 11.11 HBB IFNG IL10
14 11.02 CD40LG IFNG IL4
15 10.9 IFNG IL10 IL4
16 10.75 IFNG IL10 IL4
17 10.61 CD40LG HBB IFNG IL10

GO Terms for Buruli Ulcer

Cellular components related to Buruli Ulcer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 actin cortical patch GO:0030479 8.62 WAS WASL

Biological processes related to Buruli Ulcer according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.93 ATF4 IL10 IL4 SLC11A1 WAS WASL
2 regulation of signaling receptor activity GO:0010469 9.86 CD40LG IFNG IL10 IL4
3 positive regulation of gene expression GO:0010628 9.84 ATF4 IFNG IL4 SLC11A1
4 B cell differentiation GO:0030183 9.61 CD40LG IL10 IL4
5 positive regulation of interleukin-12 production GO:0032735 9.57 CD40LG IFNG
6 response to interferon-gamma GO:0034341 9.55 SEC61A1 SLC11A1
7 actin filament-based movement GO:0030048 9.52 WAS WASL
8 defense response to protozoan GO:0042832 9.51 IL10 SLC11A1
9 actin polymerization or depolymerization GO:0008154 9.49 WAS WASL
10 positive regulation of actin nucleation GO:0051127 9.48 WAS WASL
11 positive regulation of Arp2/3 complex-mediated actin nucleation GO:2000601 9.4 WAS WASL
12 positive regulation of MHC class II biosynthetic process GO:0045348 9.37 IL10 IL4
13 actin cortical patch assembly GO:0000147 9.32 WAS WASL
14 actin cortical patch localization GO:0051666 9.26 WAS WASL
15 regulation of isotype switching GO:0045191 9.16 IL10 IL4
16 immune response GO:0006955 9.1 CD40LG IFNG IL10 IL4 SLC11A1 WAS
17 type 2 immune response GO:0042092 8.96 IL10 IL4

Molecular functions related to Buruli Ulcer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 GTPase regulator activity GO:0030695 8.96 WAS WASL
2 cytokine activity GO:0005125 8.92 CD40LG IFNG IL10 IL4

Sources for Buruli Ulcer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....